Differential clinicopathologic features of EGPA-associated neuropathy with and without ANCA
- 21 April 2020
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 94 (16), E1726-E1737
- https://doi.org/10.1212/WNL.0000000000009309
Abstract
Objective To investigate the clinicopathologic features of eosinophilic granulomatosis with polyangiitis (EGPA)-associated neuropathy with a focus on the presence or absence of anti-neutrophil cytoplasmic antibodies (ANCAs). Methods We examined the clinical features and pathologic findings of sural nerve biopsy specimens from 82 patients with EGPA-associated neuropathy. Of these patients, 32.9% were myeloperoxidase (MPO)-ANCA positive, and 67.1% were MPO-ANCA negative. PR3-ANCA was negative in all of 78 examined patients. Results Upper limb symptoms were more frequently reported as initial neuropathic manifestations in the MPO-ANCA-positive group than in the MPO-ANCA-negative group (44.4% vs 14.6%, p < 0.01). The serum levels of C-reactive protein were significantly higher in the MPO-ANCA-positive group than in the MPO-ANCA-negative group (p < 0.05). Sural nerve biopsy specimens showed findings suggestive of vasculitis (i.e., destruction of vascular structures) in epineurial vessels; these results were seen more frequently in the MPO-ANCA-positive group than in the MPO-ANCA-negative group (p < 0.0001). Conversely, the numbers of eosinophils in the lumen of the epineurial vessels (p < 0.01) and epineurial vessels occluded by intraluminal eosinophils (p < 0.05) were higher in the MPO-ANCA-negative group than in the MPO-ANCA-positive group. Furthermore, the incidence of eosinophil infiltration in the endoneurium was higher in the MPO-ANCA-negative group than in the MPO-ANCA-positive group (p < 0.01). Conclusions This study suggests that the pathogenesis of EGPA comprises at least 2 distinct mechanisms: ANCA-associated vasculitis resulting in ischemic effects and inflammation, which is prominent in MPO-ANCA-positive patients, and eosinophil-associated vascular occlusion leading to ischemia and eosinophil-associated tissue damage, which is conspicuous in MPO-ANCA-negative patients.This publication has 47 references indexed in Scilit:
- Eosinophilic granulomatosis with polyangiitis (Churg–Strauss): state of the artAllergy, 2013
- A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg–Strauss, EGPA): monocentric experiences in 150 patientsAnnals Of The Rheumatic Diseases, 2012
- Elderly cases of Churg–Strauss syndrome: Case report and review of Japanese casesThe Journal of Dermatology, 2011
- Guideline for Management of Vasculitis Syndrome (JCS 2008) - Digest Version -Circulation Journal, 2011
- Peripheral Nerve Society Guideline* on the classification, diagnosis, investigation, and immunosuppressive therapy of non‐systemic vasculitic neuropathy: executive summaryJournal of the Peripheral Nervous System, 2010
- Refining the definition of hypereosinophilic syndromeJournal of Allergy and Clinical Immunology, 2010
- Neuropathic pain correlates with myelinated fibre loss and cytokine profile in POEMS syndromeJournal of Neurology, Neurosurgery & Psychiatry, 2008
- ANCA-associated Vasculitis: Diagnostic Therapeutic StrategyAllergology International, 2007
- Age associated axonal features in HNPP with 17p11.2 deletion in JapanJournal of Neurology, Neurosurgery & Psychiatry, 2005
- Wegener Granulomatosis: An Analysis of 158 PatientsAnnals of Internal Medicine, 1992